RS50540B - Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga - Google Patents
Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz togaInfo
- Publication number
- RS50540B RS50540B RSP-2008/0068A RSP20080068A RS50540B RS 50540 B RS50540 B RS 50540B RS P20080068 A RSP20080068 A RS P20080068A RS 50540 B RS50540 B RS 50540B
- Authority
- RS
- Serbia
- Prior art keywords
- alkoxy
- alkyl
- group
- modulators
- metabolism
- Prior art date
Links
- 125000000714 pyrimidinyl group Chemical group 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 125000004076 pyridyl group Chemical group 0.000 title 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- -1 C1-4alkylcarboxamide Chemical group 0.000 abstract 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Jedinjenje odabrano od jedinjenja formule (la) i njihove farmaceutski prihvatljive soli, solvati i hidrati: naznačena time, što:X je N ili CR8 pri čemu je R8 H ili halogen; Y je NH ili O; Z je CH ili N;R1 je karbo-C1-C6-alkoksi, oksadiazolii ili pirimidinil gde su navedeni karbo-C1-C6-alkoksi, oksadiazolil ili pirimidinil svaki opciono supstituisani sa 1 ili 2 supstituentima nezavisno odabranim od grupe koja se sastoji od -C1-4 alkil, -C1-4-alkoksi i C3-5 cikloalkil; R2 je H ili C1-4 alkil;R3 je C1-4 alkoksi, O-C2-4-alkinil ili hidroksil;R4 je odabran od grupe koja se sastoji od H, C1-4 alkoksi, C1-4 alkil, C2-4 alkinil i halogen;R5 je odabran od grupe koja se sastoji od C1-4 acilsulfonamid, C1-4 alkoksi, C1-4 alkil, C1-4 alkilamino, C1-4 alkilsulfonil, C1-4 alkiltio, cijano, heterociklil, di-C1-4-dialkilamino i silfonamid, pri čemu su navedeni C1-4 alkoksi, C1-4 alkil, C1-4 alkilamino, C1-4 alkilsulfonil, C1-4 alkiltio, di- C1-4 dialkilamino i heterociklil svaki opciono supstituisani sa 1 ili 2 supstituenata nezavisno odabranih od grupe koja se sastoji od C2-4.alkinil, C1.4alkoksi, C1.4alkilkarboksamid, C1-4 alkilsulfonil, C3-5cikloalkil, C3-5cikloalkiloksi, di-C1-4-alkilkaboksamid, hidroksil i fosfonooksi, pri čemu je navedeni C1-4 alkilkarboksamid opciono supstituisan sa hidroksil; ili R5 je grupa Formule (A): pri čemu su:m, n i q svaki nezavisno 0, 1, 2 ili 3;r je 0, 1 ili 2; i t je 0 ili 1; R6 je H ili halogen; i R7 je H ili C1-4alkilPrijava sadrži još 61 patentni zahtev.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64284005P | 2005-01-10 | 2005-01-10 | |
| PCT/US2006/000567 WO2006083491A2 (en) | 2005-01-10 | 2006-01-09 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS50540B true RS50540B (sr) | 2010-05-07 |
Family
ID=36755755
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2008/0068A RS50540B (sr) | 2005-01-10 | 2006-01-09 | Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga |
| RSP-2009/0523A RS51007B (sr) | 2005-01-10 | 2006-01-09 | Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2009/0523A RS51007B (sr) | 2005-01-10 | 2006-01-09 | Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20060155128A1 (sr) |
| EP (2) | EP1732562B1 (sr) |
| JP (1) | JP2008526882A (sr) |
| KR (1) | KR20070098907A (sr) |
| CN (2) | CN101115740A (sr) |
| AR (1) | AR054320A1 (sr) |
| AT (2) | ATE446293T1 (sr) |
| AU (1) | AU2006211583C1 (sr) |
| BR (1) | BRPI0606704A (sr) |
| CA (1) | CA2594466A1 (sr) |
| CR (1) | CR9225A (sr) |
| CY (2) | CY1107215T1 (sr) |
| DE (2) | DE602006000339T2 (sr) |
| DK (2) | DK1911756T3 (sr) |
| EA (1) | EA015714B1 (sr) |
| ES (2) | ES2333824T4 (sr) |
| GE (1) | GEP20094828B (sr) |
| GT (1) | GT200600006A (sr) |
| HN (2) | HN2006000969A (sr) |
| HR (2) | HRP20080113T3 (sr) |
| IL (1) | IL184363A0 (sr) |
| MX (1) | MX2007008402A (sr) |
| MY (1) | MY148521A (sr) |
| NI (1) | NI200700169A (sr) |
| NO (1) | NO20073806L (sr) |
| NZ (1) | NZ556220A (sr) |
| PE (2) | PE20091590A1 (sr) |
| PL (2) | PL1732562T3 (sr) |
| PT (2) | PT1732562E (sr) |
| RS (2) | RS50540B (sr) |
| SG (1) | SG158875A1 (sr) |
| SI (2) | SI1732562T1 (sr) |
| TW (1) | TW200637845A (sr) |
| UA (1) | UA89812C2 (sr) |
| WO (1) | WO2006083491A2 (sr) |
| ZA (1) | ZA200705471B (sr) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
| DE602004017703D1 (de) * | 2003-02-24 | 2008-12-24 | Arena Pharm Inc | Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| MXPA06014129A (es) * | 2004-06-04 | 2007-03-07 | Arena Pharm Inc | Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos. |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| JP2008545760A (ja) * | 2005-06-09 | 2008-12-18 | メルク フロスト カナダ リミテツド | ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしてのアザシクロヘキサン誘導体 |
| JP2008546661A (ja) | 2005-06-14 | 2008-12-25 | エフ．ホフマン−ラ ロシュ アーゲー | アントラニル酸誘導体 |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| ES2326391T3 (es) * | 2005-09-16 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo. |
| PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| SI1971862T1 (sl) | 2006-04-11 | 2011-02-28 | Arena Pharm Inc | Postopki uporabe GPR119 receptorja za identificiranje spojin, uporabnih za povečanje kostne mase pri posamezniku |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| ES2388967T3 (es) * | 2007-05-04 | 2012-10-22 | Bristol-Myers Squibb Company | Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G |
| JP2010526146A (ja) * | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト |
| SI2173737T1 (sl) * | 2007-07-17 | 2012-05-31 | Bristol Myers Squibb Co | Metoda za modulacijo gpr g proteinsko sklopljenega receptorja in izbrane spojine |
| JP5489997B2 (ja) | 2007-07-19 | 2014-05-14 | シマベイ セラピューティクス， インコーポレーテッド | 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101801954B (zh) * | 2007-09-20 | 2013-10-09 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
| NZ585284A (en) * | 2007-10-16 | 2011-03-31 | Daiichi Sankyo Co Ltd | Pyrimidyl indoline compounds with hypoglycaemic effect useful in the treatment of diabetes related diseases and adiposity |
| US8907095B2 (en) * | 2007-10-22 | 2014-12-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 |
| EP2259678A4 (en) * | 2008-02-29 | 2011-07-27 | Cylene Pharmaceuticals Inc | PROTEIN KINASE MODULATORS |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| CN102203074A (zh) * | 2008-06-20 | 2011-09-28 | 麦它波莱克斯股份有限公司 | 芳基gpr119激动剂及其用途 |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| EP2344195A2 (en) * | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| WO2010059384A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| WO2010059385A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidne derivatives useful as gdir agonists |
| US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| WO2010075269A1 (en) * | 2008-12-23 | 2010-07-01 | Schering Corporation | Pyrimidine derivatives as gpcr modttlators for use in the treatment of obesity and diabetes |
| NZ592924A (en) | 2008-12-23 | 2014-05-30 | Boehringer Ingelheim Int | Salt forms of a xanthine derivative |
| US8410122B2 (en) | 2008-12-23 | 2013-04-02 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| EP2399914A4 (en) * | 2009-02-18 | 2012-08-29 | Takeda Pharmaceutical | FUSED HETEROCYCLIC CORE COMPOUND |
| TW201039827A (en) * | 2009-04-15 | 2010-11-16 | Daiichi Sankyo Co Ltd | Indoline compound |
| WO2010135505A2 (en) * | 2009-05-20 | 2010-11-25 | Janssen Pharmaceutica Nv | Crystalline forms of 4-[6-(6-methanesulfonyl-2-methylpyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
| WO2010135506A1 (en) * | 2009-05-20 | 2010-11-25 | Janssen Pharmaceutica Nv | Process for the preparation of 4- [6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino) -5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| WO2010149684A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011041154A1 (en) * | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| CN102933576A (zh) | 2010-04-08 | 2013-02-13 | 百时美施贵宝公司 | 作为gpr119调节剂的嘧啶基哌啶基氧基吡啶酮类似物 |
| US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| EP2566860B1 (en) | 2010-05-06 | 2014-09-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
| EP2566862B1 (en) | 2010-05-06 | 2015-09-16 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| WO2011163090A1 (en) | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| KR20130101524A (ko) | 2010-09-01 | 2013-09-13 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염 |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| EP2611782A1 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
| MX2013002430A (es) | 2010-09-01 | 2013-07-22 | Arena Pharm Inc | Formas de dosis de disolucion de rápida de agonistas de 5-ht2c. |
| WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| PL2625177T3 (pl) * | 2010-10-08 | 2015-12-31 | Cadila Healthcare Ltd | Nowi agoniści GPR 119 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US9000175B2 (en) | 2010-11-26 | 2015-04-07 | Lupin Limited | Bicyclic GPR119 modulators |
| US8853213B2 (en) | 2011-01-03 | 2014-10-07 | Hanmi Pharm. Co., Ltd | Bicyclic compound for modulating G protein-coupled receptors |
| US20140038889A1 (en) * | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| ES2602813T3 (es) | 2011-06-09 | 2017-02-22 | Rhizen Pharmaceuticals S.A. | Nuevos compuestos como moduladores de GPR-119 |
| CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| EP2850073B1 (en) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| KR20150132311A (ko) * | 2013-03-15 | 2015-11-25 | 나이키 이노베이트 씨.브이. | 파형부 구조체를 포함한 밑창 구조체를 포함하는 신발류 물품 |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3310760B8 (en) | 2015-06-22 | 2022-10-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders |
| KR102391564B1 (ko) | 2016-06-10 | 2022-04-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴 및 메트포르민의 병용물 |
| US10292983B2 (en) | 2016-08-03 | 2019-05-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| WO2018048953A1 (en) * | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| US20200129511A1 (en) | 2017-06-19 | 2020-04-30 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of nafld and nash |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| CN108658871B (zh) * | 2018-06-19 | 2020-10-30 | 舞阳威森生物医药有限公司 | 周效磺胺中间体4,6-二氯-5-甲氧基嘧啶的制备方法 |
| CN108892635A (zh) * | 2018-09-07 | 2018-11-27 | 江苏工程职业技术学院 | 一种西沙必利关键中间体的制备方法 |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US618777A (en) * | 1899-01-31 | Window | ||
| US427174A (en) * | 1890-05-06 | Minor c | ||
| CH389134A (de) | 1960-03-15 | 1965-03-15 | Ciba Geigy | Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe |
| CH499528A (de) | 1965-10-22 | 1970-11-30 | Ciba Geigy Ag | Verfahren zur Herstellung neuer Pyrimidine |
| CH480410A (de) * | 1967-01-09 | 1969-10-31 | Geigy Ag J R | Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen |
| CA961052A (en) | 1967-01-12 | 1975-01-14 | Max Schellenbaum | N-2-ethylhexyl-n'-aryl ureas and preparation containing them |
| FR1593586A (sr) | 1967-10-17 | 1970-06-01 | ||
| US3608087A (en) | 1968-06-21 | 1971-09-21 | Merck & Co Inc | Feed compositions |
| US3887329A (en) | 1969-05-05 | 1975-06-03 | Ciba Geigy Ag | Hexamethyl phosphotriamide-dye compositions |
| BE756953A (fr) | 1969-10-02 | 1971-04-01 | Merck & Co Inc | Potentialisation d'antibiotiques |
| US3686238A (en) | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US3852434A (en) | 1970-09-11 | 1974-12-03 | Merck & Co Inc | Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof |
| US3966744A (en) | 1971-01-11 | 1976-06-29 | Syva Company | Spin labeled compounds |
| US3690834A (en) | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
| DE2106585A1 (de) | 1971-02-11 | 1972-08-24 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Aminothiodiazole und Thiodiazol-Azofarbstoffe |
| CH560197A5 (en) | 1971-05-17 | 1975-03-27 | Ciba Geigy Ag | 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides |
| CH558137A (de) | 1971-05-17 | 1975-01-31 | Ciba Geigy Ag | Mittel zur beeinflussung des pflanzenwachstums. |
| US3966764A (en) | 1972-07-10 | 1976-06-29 | Syva Company | Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs |
| US3849420A (en) | 1972-10-20 | 1974-11-19 | Dow Chemical Co | Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines |
| CH574206A5 (sr) * | 1972-11-16 | 1976-04-15 | Ciba Geigy Ag | |
| DE2340569C2 (de) | 1973-08-10 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Azofarbstoffe |
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| US4101541A (en) | 1973-12-21 | 1978-07-18 | Ciba-Geigy Corporation | 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs |
| CH584739A5 (sr) | 1973-12-21 | 1977-02-15 | Ciba Geigy Ag | |
| FR2258841B1 (sr) | 1974-01-29 | 1977-11-04 | Ugine Kuhlmann | |
| AT327605B (de) | 1974-05-06 | 1976-02-10 | Ciba Geigy Ag | Mittel zur hemmung des pflanzenwachstums |
| AU492126B2 (en) | 1974-05-14 | 1975-11-20 | Ciba-Geigy Ag | Nitropyrimidine derivatives |
| FR2306697A1 (fr) | 1975-04-10 | 1976-11-05 | Sogeras | Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants |
| DE2731264A1 (de) | 1977-07-11 | 1979-02-01 | Boehringer Mannheim Gmbh | Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen |
| JPS6038696B2 (ja) | 1977-12-09 | 1985-09-02 | コニカ株式会社 | ハロゲン化銀カラ−写真感光材料 |
| US4242507A (en) | 1978-02-23 | 1980-12-30 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonic acid esters |
| DE2831580C2 (de) * | 1978-07-18 | 1980-09-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Reagens zur Bestimmung von Glycerin |
| DE2831850A1 (de) | 1978-07-20 | 1980-02-07 | Basf Ag | N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel |
| DE2906603A1 (de) | 1979-02-21 | 1980-09-04 | Boehringer Mannheim Gmbh | N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel |
| DOP1981004033A (es) | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| DE3334455A1 (de) | 1983-03-04 | 1984-09-06 | Bayer Ag, 5090 Leverkusen | Guanidin - derivate |
| ZA848275B (en) | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
| DE3406329A1 (de) | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
| PH22302A (en) | 1985-02-11 | 1988-07-22 | Fujisawa Pharmaceutical Co | Piperidine compounds |
| ZA861446B (en) | 1985-03-01 | 1986-10-29 | Duphar Int Res | Benzoyl urea derivatives having anti-tumor activity |
| DE3601196A1 (de) * | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
| CA1340284C (en) | 1987-03-19 | 1998-12-22 | Zeneca Inc. | Herbicidal substituted cyclic diones |
| DE68926687T2 (de) | 1988-01-11 | 1997-03-06 | Fuji Photo Film Co Ltd | Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern |
| CA2070978A1 (en) | 1991-06-11 | 1992-12-12 | William J. Greenlee | Cyclic renin inhibitors |
| EP0556889A1 (en) | 1992-02-18 | 1993-08-25 | Duphar International Research B.V | Method of preparing aryl(homo)piperazines |
| TW237456B (sr) | 1992-04-09 | 1995-01-01 | Ciba Geigy | |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB9400889D0 (en) | 1994-01-18 | 1994-03-16 | Sandoz Ltd | Novel compounds |
| TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| ES2218552T3 (es) * | 1994-09-09 | 2004-11-16 | Nippon Shinyaku Company, Limited | Derivado heterociclico y medicina. |
| CA2206307A1 (en) | 1994-11-29 | 1996-06-06 | Dainippon Pharmaceutical Co., Ltd. | Indole derivative |
| US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US6956047B1 (en) * | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| WO1997015549A1 (en) | 1995-10-26 | 1997-05-01 | Tokyo Tanabe Company Limited | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME |
| US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| DE19602095A1 (de) | 1996-01-22 | 1997-07-24 | Bayer Ag | Halogenpyrimidine |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6008234A (en) * | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| CA2229123A1 (en) | 1997-02-11 | 1998-08-11 | Mitchell Irvin Steinberg | Pharmaceutical agents |
| DE19737723A1 (de) | 1997-08-14 | 1999-02-18 | Bayer Ag | Methoximinomethyloxadiazine |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| US6239126B1 (en) * | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU5020400A (en) * | 1999-05-20 | 2000-12-12 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| EP1074549B1 (en) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| DE19962936A1 (de) | 1999-12-24 | 2001-06-28 | Bayer Ag | Neue beta-Aminosäureverbindungen als Integrinantagonisten |
| US6569879B2 (en) * | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| EP1287133B1 (en) | 2000-05-18 | 2006-12-13 | Bayer HealthCare AG | Regulation of human dopamine-like g protein-coupled receptor |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| WO2002002539A1 (en) * | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| CA2427610A1 (en) * | 2000-10-31 | 2002-08-08 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| US20020058026A1 (en) * | 2000-11-13 | 2002-05-16 | Milton Hammerly | HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10 |
| WO2002040458A1 (fr) | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Derives d'isoxazole |
| US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
| US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
| US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
| PL205343B1 (pl) * | 2001-01-26 | 2010-04-30 | Schering Corp | Zastosowanie inhibitora wchłaniania sterolu |
| AU2002316421B2 (en) | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
| WO2004013997A1 (en) | 2001-08-02 | 2004-02-12 | Halliburton Energy Service, Inc. | Adaptive acoustic transmitter controller apparatus and method |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| US20070225351A1 (en) * | 2002-01-11 | 2007-09-27 | Lippa Arnold S | Methods and compositions for controlling body weight and appetite |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| JP4533134B2 (ja) * | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
| GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| US20060014717A1 (en) | 2002-06-28 | 2006-01-19 | Glykos Finland Oy | Therapeutic compositions for use in prophylaxis or treatment of diarrheas |
| US7071210B2 (en) | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| JP4530852B2 (ja) | 2002-07-15 | 2010-08-25 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤 |
| EP1539137B1 (en) | 2002-07-30 | 2010-05-26 | Merck Sharp & Dohme Corp. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| CA2491733A1 (en) | 2002-07-30 | 2004-02-05 | Merck & Co., Inc. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| RS20050161A (en) | 2002-08-08 | 2007-09-21 | Amgen Inc., | Vanilloid receptor ligands and their use in treatments |
| US20060167045A1 (en) | 2002-08-21 | 2006-07-27 | Joanne Waldstreicher | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist |
| JP4340232B2 (ja) | 2002-08-29 | 2009-10-07 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
| HRP20050181A2 (en) | 2002-08-29 | 2006-03-31 | Merck & Co. Inc. | Indoles having anti-diabetic activity |
| WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| AU2003284111A1 (en) | 2002-10-09 | 2004-05-04 | Genaissance Pharmaceuticals, Inc. | Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol |
| JP2006507302A (ja) | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | キナーゼ阻害剤 |
| US7098235B2 (en) * | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| US20040110241A1 (en) * | 2002-12-06 | 2004-06-10 | Segal Mark S. | Materials and methods for monitoring vascular endothelial function |
| AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| AU2003299790A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
| WO2004066963A2 (en) | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| DE602004017703D1 (de) * | 2003-02-24 | 2008-12-24 | Arena Pharm Inc | Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus |
| JP2004269468A (ja) | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| JP2004269469A (ja) | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| WO2004085401A1 (en) | 2003-03-28 | 2004-10-07 | Pfizer Products Inc. | 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
| TWI393560B (zh) | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| EP1475094B8 (en) | 2003-05-06 | 2011-01-12 | Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) | Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| EP1635773A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. (a New Jersey corp.) | Combination therapy for the treatment of hypertension |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| JP4920410B2 (ja) * | 2003-07-14 | 2012-04-18 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療 |
| FI116461B (fi) * | 2004-03-18 | 2005-11-30 | Kone Corp | Menetelmä hissin asentamiseksi ja hissin toimituskokonaisuus |
| MXPA06014129A (es) * | 2004-06-04 | 2007-03-07 | Arena Pharm Inc | Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos. |
| US20080167321A1 (en) | 2004-09-20 | 2008-07-10 | Xenon Pharmaceuticals Inc. | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase |
| ATE481969T1 (de) | 2004-10-01 | 2010-10-15 | Merck Sharp & Dohme | Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes |
| CN101084018B (zh) | 2004-11-03 | 2013-12-18 | 艾尼纳制药公司 | 用于治疗胰岛素相关病症的gpr41和其调节剂 |
| DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| CN101107245A (zh) | 2005-01-19 | 2008-01-16 | 神经能质公司 | 经杂芳基取代的哌嗪-吡啶类似物 |
| PT1899329E (pt) | 2005-07-01 | 2012-01-13 | Irm Llc | Derivados de benzimidazole substituídos por pirimidina como inibidores de proteína quinase |
| TW200745055A (en) | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| ES2684821T3 (es) | 2005-12-29 | 2018-10-04 | Lexicon Pharmaceuticals, Inc. | Derivados de aminoácidos multicíclicos y métodos de su uso |
| JP5237115B2 (ja) * | 2006-01-19 | 2013-07-17 | オーキッド リサーチ ラボラトリーズ リミテッド | 新規複素環類 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
-
2006
- 2006-01-04 MY MYPI2010006219A patent/MY148521A/en unknown
- 2006-01-06 PE PE2009001073A patent/PE20091590A1/es not_active Application Discontinuation
- 2006-01-06 PE PE2006000046A patent/PE20060857A1/es not_active Application Discontinuation
- 2006-01-09 AU AU2006211583A patent/AU2006211583C1/en not_active Ceased
- 2006-01-09 AT AT07023528T patent/ATE446293T1/de active
- 2006-01-09 DE DE602006000339T patent/DE602006000339T2/de active Active
- 2006-01-09 AR ARP060100071A patent/AR054320A1/es not_active Application Discontinuation
- 2006-01-09 SG SG201000207-9A patent/SG158875A1/en unknown
- 2006-01-09 DE DE602006009946T patent/DE602006009946D1/de active Active
- 2006-01-09 MX MX2007008402A patent/MX2007008402A/es active IP Right Grant
- 2006-01-09 TW TW095100772A patent/TW200637845A/zh unknown
- 2006-01-09 NZ NZ556220A patent/NZ556220A/en not_active IP Right Cessation
- 2006-01-09 EP EP06733644A patent/EP1732562B1/en active Active
- 2006-01-09 HN HN2006000969A patent/HN2006000969A/es unknown
- 2006-01-09 WO PCT/US2006/000567 patent/WO2006083491A2/en active Application Filing
- 2006-01-09 CN CNA2006800044893A patent/CN101115740A/zh active Pending
- 2006-01-09 SI SI200630025T patent/SI1732562T1/sl unknown
- 2006-01-09 CN CN201010617617XA patent/CN102125555A/zh active Pending
- 2006-01-09 RS RSP-2008/0068A patent/RS50540B/sr unknown
- 2006-01-09 PT PT06733644T patent/PT1732562E/pt unknown
- 2006-01-09 PL PL06733644T patent/PL1732562T3/pl unknown
- 2006-01-09 GE GEAP200611119A patent/GEP20094828B/en unknown
- 2006-01-09 EP EP07023528A patent/EP1911756B9/en active Active
- 2006-01-09 ES ES07023528T patent/ES2333824T4/es active Active
- 2006-01-09 US US11/327,896 patent/US20060155128A1/en not_active Abandoned
- 2006-01-09 PL PL07023528T patent/PL1911756T3/pl unknown
- 2006-01-09 GT GT200600006A patent/GT200600006A/es unknown
- 2006-01-09 JP JP2007550520A patent/JP2008526882A/ja active Pending
- 2006-01-09 UA UAA200709148A patent/UA89812C2/ru unknown
- 2006-01-09 PT PT07023528T patent/PT1911756E/pt unknown
- 2006-01-09 SI SI200630527T patent/SI1911756T1/sl unknown
- 2006-01-09 CA CA002594466A patent/CA2594466A1/en not_active Abandoned
- 2006-01-09 HR HR20080113T patent/HRP20080113T3/xx unknown
- 2006-01-09 RS RSP-2009/0523A patent/RS51007B/sr unknown
- 2006-01-09 DK DK07023528.8T patent/DK1911756T3/da active
- 2006-01-09 ES ES06733644T patent/ES2299167T4/es active Active
- 2006-01-09 KR KR1020077018314A patent/KR20070098907A/ko not_active Ceased
- 2006-01-09 EA EA200701471A patent/EA015714B1/ru not_active IP Right Cessation
- 2006-01-09 BR BRPI0606704-2A patent/BRPI0606704A/pt not_active IP Right Cessation
- 2006-01-09 DK DK06733644T patent/DK1732562T3/da active
- 2006-01-09 AT AT06733644T patent/ATE381558T1/de active
- 2006-07-06 US US11/482,777 patent/US8362248B2/en active Active
- 2006-11-20 US US11/601,927 patent/US20070078150A1/en not_active Abandoned
-
2007
- 2007-07-02 IL IL184363A patent/IL184363A0/en unknown
- 2007-07-03 CR CR9225A patent/CR9225A/es not_active Application Discontinuation
- 2007-07-04 NI NI200700169A patent/NI200700169A/es unknown
- 2007-07-04 ZA ZA200705471A patent/ZA200705471B/en unknown
- 2007-07-20 NO NO20073806A patent/NO20073806L/no not_active Application Discontinuation
-
2008
- 2008-02-27 CY CY20081100225T patent/CY1107215T1/el unknown
-
2009
- 2009-12-31 CY CY20091101355T patent/CY1109696T1/el unknown
-
2010
- 2010-01-07 HR HR20100008T patent/HRP20100008T1/hr unknown
- 2010-03-05 HN HN2010000430A patent/HN2010000430A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS50540B (sr) | Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
| RS52978B (sr) | Fuzionisan amino piridin kao hsp90 inhibitori | |
| RS50755B (sr) | Supstituisani aril i heteroaril derivati kao modulatori metabolizma i profilakse i lečenje poremećaja proisteklih iz toga | |
| RS50698B (sr) | 3-FENIL-PIRAZOL DERIVATI KAO MODULATORI 5-HT-2a SEROTONIN RECEPTORA KORISNI ZA LEČENJE SA TIM POVEZANIH POREMEĆAJA | |
| EP1724262A4 (en) | 1- (2H) -ISOCHINOLONDERIVAT | |
| CY1114932T1 (el) | Αντιπαρασιτικοι παραγοντες | |
| RS50519B (sr) | Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona | |
| EA200602058A1 (ru) | Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| TW200745061A (en) | Macrocylic inhibitors of hepatitis C virus | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| HRP20060100T3 (en) | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | |
| RS50537B (sr) | Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| MXPA05008584A (es) | Compuestos heterociclicos utiles como activadores de nurr-1. | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| NO20065863L (no) | 3-[4-(6-(4,5-dihydroisoksazol-3-yl]pyridin-3-yl)-3-fenyl]-5-(1 H,1,2,3-triazol-1-yl-metyl)-1,3-oksazolidin-2-oner som antibakterielle midler | |
| RS51126B (sr) | Postupak za pripremanje mezilata piperazin derivata | |
| NO20081068L (no) | Kinolinderivater som antibakterielle midler | |
| AR049323A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de igf-1r y composiciones farmaceuticas que los componen. | |
| DE602004012400D1 (de) | N-ä(piperazinyl)hetarylüarylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor | |
| TW200607808A (en) | Pyrido-pyrimidine derivatives, preparation thereof and application thereof | |
| TW200609218A (en) | Bicyclic compounds | |
| HRP20080097T5 (en) | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists |